pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Foundayo · news · pharmadog
← back to Foundayo
News mentioning Foundayo
66
stories
8d
Blackstone bets $1.5B on Pfizer’s obesity drug
biopharma dive
9d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
11d
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
biospace
11d
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
biospace
11d
STAT+: Heart association meeting’s readout is trending ‘neutral’
stat
11d
STAT+: Eli Lilly’s GLP-1 pill Foundayo helped alleviate sleep apnea in studies
stat
14d
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
biopharma dive
14d
This week in charts: 3 drug launches Wall Street is watching
biopharma dive
16d
Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
biopharma dive
16d
Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
biospace
21d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
22d
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
22d
Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial
fiercebiotech
23d
5 new drug launches that defied industry expectations
biospace
25d
Corxel, an obesity drugmaker, to go public via SPAC deal
biopharma dive
Oct 21, 26
Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients
biospace
Oct 14, 26
Deep-pocketed Verdiva axes GLP-1 switching trial over ‘market evolution’
fiercebiotech
Oct 14, 26
Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear unconvinced
fiercebiotech
Sep 30, 26
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
Sep 22, 26
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
Sep 21, 26
Novo talks up drug launches in effort to win back investors
biopharma dive
Sep 21, 26
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
Sep 21, 26
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Sep 17, 26
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
Sep 14, 26
Lilly cans early experimental obesity drug after ‘high bar’ not met
fiercebiotech
Sep 14, 26
Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
fiercebiotech
Sep 14, 26
No more Nordisk as Novo goes it alone amid rebranding push
fiercebiotech
Sep 9, 26
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
Sep 8, 26
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
biospace
Aug 27, 26
Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
biospace
← prev
page 1 of 3
next →